跳至主要内容
临床试验/NCT01331473
NCT01331473Unknown3 期

PROximal Protection VErsus NON-Protection in Carotid Artery Stenting (PROVENON Study) A Randomized Prospective MRI-based Trial.

Universität des Saarlandes2 个研究点 分布在 1 个国家目标入组 220 人开始时间: 2011年5月最近更新:
适应症

试验速览

阶段
3 期
入组人数
220
试验地点
2
主要终点
The detection rate of new hyper-intense DWI lesion on the post-treatment compared to the pretreatment MRI imaging

研究概览

简要总结

To compare the incidence of new ischemic brain injury detected with magnetic resonance imaging (MRI) after carotid artery stenting in patients treated with and without proximal cerebral protection (Gore Flow Reversal System).

详细描述

Primary Objective:

The purpose of this study is to compare the rate of new ischemic brain injury detectable on MRI after carotid artery stenting between patients treated with proximal cerebral protection (Gore Flow Reversal System) and without cerebral protection.

Secondary Objective:

Impact of MRI-morphology of atherosclerotic plaque to the rate of new hyperintense diffusion weighted imaging (DWI) lesion on the post-treatment scan and to the rate of ipsilateral stroke or death.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female ≥ 18 years old;
  • Suitable/Eligible for carotid artery revascularization;
  • Significant artery stenosis in symptomatic patients defined as ≥ 50% of the artery diameter (%DS) or asymptomatic ≥ 80 %DS by angiography. Symptomatic is defined as a carotid artery stenosis associated with ipsilateral transient ischemic attack (TIA), amaurosis fugax, ischemic stroke or retinal infarction within 6 months prior to enrollment.
  • Adequate clinical conditions to perform DW-MRI.
  • Ability of the individual to understand the character and the consequences of clinical trial.
  • Signed and dated informed consent provided before the beginning of any intervention.
  • Negative pregnancy test (serum or urine) and contraception use for any woman of childbearing age. Systematic contraceptives (oral, implant, injection) and dia-phragm or condoms with spermicidal are considered reliable. Women who have undergone bilateral oophorectomy or/and hysterectomy or women status post-menopausal for at least two years are eligible for this trial.

排除标准

  • Intracranial hemorrhage, hemorrhagic stroke, or stroke with mass effect demonstrated on CT scan or MRI within 30 days of the index procedure.
  • Persisting ischemic stroke (defined as either a score > 15 on the NIH stroke scale, a Rankin score > 3 or a Barthel score < 60 measured within one week prior to study entry).
  • Intracranial mass lesion (i.e., abscess, tumor, or other infection).
  • peripheral vascular, supra-aortic or internal carotid artery tortuosity precluding the use of catheter-based techniques required for successful results.
  • Lactation.
  • Arterio-venous malformation in the territory of the target carotid artery.
  • Any disease or medication that affects local hemostasis,
  • Participation in other clinical trials during the present clinical trial or within the last month.
  • Medical or psychological condition that would not permit completion of the trial or signing of informed consent.

结局指标

主要结局

The detection rate of new hyper-intense DWI lesion on the post-treatment compared to the pretreatment MRI imaging

时间窗: Day 1-3

次要结局

  • Ipsilateral stroke (ischaemic stroke, intracerebral bleeding or both, with symptoms lasting more than 24 h) or death between treatment and 30 days after treatment(Day 30)
  • Technical Success of the procedure(Day 0)
  • Access site vascular complications, defined as need for surgical repair or blood transfusion(Day 0-7)

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验